This content is machine translated Atopic dermatitis Biologics and JAK-i – the best of both worlds In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with...…
View Post 9 min This content is machine translated Journal Club: Atopic dermatitis Modern systems therapy – status quo and prospects The therapeutic landscape for atopic dermatitis is changing. New findings have made it possible to develop modern treatment options that selectively target inflammatory signaling pathways. There are currently two modern…
View Post 7 min This content is machine translated Biologics for AD Interleukin-13 as a target – new long-term data available Now that the range of systemic therapeutics for atopic dermatitis has been expanded and the two monoclonal antibodies dupilumab and tralokinumab as well as three Janus kinase inhibitors have been…
View Post 7 min This content is machine translated Atopic dermatitis: guideline update Current recommendations on biologics and JAK inhibitors With the increasing number of system therapeutics, practical advice on choosing the most suitable treatment option is becoming more important. The new edition of the S3 guideline on atopic dermatitis…
View Post 5 min This content is machine translated Atopic dermatitis Focus on mediators of type 2 inflammation The pathomechanisms of atopic dermatitis (AD) are becoming increasingly better understood. A genetically determined immunological imbalance is characterized by an increased Th2 response and is associated with the production of…
View Post 4 min This content is machine translated System therapy for atopic dermatitis: biologics or JAK inhibitors? Balancing benefits and risks The era of targeted systemic treatment began several years ago and the therapy armamentarium is constantly expanding, so that the question of selection criteria for the individually appropriate therapy is…
View Post 6 min This content is machine translated Atopic dermatitis Skin microbiome normalizes under tralokinumab therapy Atopic dermatitis is associated with dysbiosis of the cutaneous microbiome. Characteristic is reduced bacterial diversity, with Staphylococcus aureus often being the dominant bacterial genus. In a recent study, it was…
View Post 6 min This content is machine translated Atopic eczema EuroGuiDerm guideline – overview of current recommendations for system therapy Recently, there have been significant advances in the treatment of atopic dermatitis, including several new systemic therapeutic options overcoming regulatory hurdles. This has also been incorporated into the EuroGuiDerm guideline…
View Post 16 min This content is machine translated Moderate to severe atopic dermatitis Changing therapeutic landscape – broad arsenal of treatment options New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines.… CME-Test
View Post 5 min This content is machine translated Atopic dermatitis Tralokinumab – another biologic with an excellent benefit-risk profile Since the beginning of June this year, tralokinumab – a human monoclonal IgG4 antibody that specifically binds with high affinity to the cytokine IL-13 – has been approved for adults…
View Post 5 min This content is machine translated "Beyond skin" Tralokinumab: long-term perspectives for patients with atopic dermatitis An excessive Th2 immune response is characteristic of atopic dermatitis. Biologics specifically interfere with signaling cascades of Th2 inflammatory processes. Recently developed novel drugs include tralokinumab. Meanwhile, impressive efficacy evidence from…
